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Abstract
Background: Artemisinin derivatives have been used for malaria treatment in Vietnam since 1989. Reported malaria 
cases have decreased from 1,672,000 with 4,650 deaths in 1991, to 91,635 with 43 deaths in 2006. Current national 
guidelines recommend artemisinin-based combination therapy (ACT), although artesunate is still available as 
monotherapy through the private sector. Recent reports suggest that effectiveness of ACT and artesunate 
monotherapy has declined in western Cambodia. This study examined Plasmodium falciparum resistance patterns over 
10 years in southwest Vietnam in infected patients treated with artemisinin compounds.
Methods: The study was conducted in two communes in Phuoc Long district, Binh Phuoc province, 100 km west of 
the Cambodian border. This was chosen as a likely site for emerging artemisinin resistance because of the high 
prevalence of P. falciparum malaria, and the length of time that artemisinin had been in use. In vivo and in vitro 
monitoring of P. falciparum susceptibility to anti-malarial drugs was conducted in 1998, 2001, 2004/5, and 2008/9. 
Patients with confirmed P. falciparum malaria received therapy with 5 or 7 days of artemisinin (1998 and 2001 
respectively) or 7 days of artesunate
Results: In the four surveys, 270 patients were recruited and treated. The mean parasite clearance times differed 
between 1998, 2001 and 2004/5 (1.8, 2.3 and 2.1 days, P < 0.01) but not between 1998 and 2008/2009. The mean 
parasite clearance times were correlated with parasite density at day 0 (r = 0.4; P < 0.001). Treatment failure rates after 
PCR adjustment were 13.8%, 2.9%, 1.2%, and 0% respectively. Susceptibility of P. falciparum to artemisinin in in vitro tests 
was stable during the period, except for a rise in EC90 and EC99 in 2001.
Conclusions: This study showed stable levels of P. falciparum sensitivity to artemisinin compounds in the two sites over 
a ten-year period. The introduction of ACT in this area in 2003 may have protected against the development of 
artemisinin resistance. Adherence to the latest WHO and Vietnamese guidelines, which recommend ACT as first-line 
therapy in all malarious areas, and continued monitoring along the Vietnam-Cambodia border will be essential to 
prevent the spread of artemisinin resistance in Vietnam.
Background
The global burden of malaria has increased during the
last decade and in 2006 there were an estimated 247 mil-
lion cases and 881,000 deaths worldwide [1]. Multi-drug
resistance has increasingly become a major impediment
to malaria control, although the discovery and evaluation
of artemisinin in China in the l970's has strengthened
global efforts to combat malaria. WHO now recom-
mends that uncomplicated P. falciparum malaria be
treated with artemisinin-based combination therapy
(ACT) to prevent recrudescence and to delay the selec-
tion of resistant strains [2]. The emergence of artemisinin
resistance would severely limit treatment options and
recent reports from Cambodia confirm that this has
already occurred in isolated locations [3-5].
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In Vietnam, artemisinin derivatives have been used for
malaria treatment since 1989. Reported malaria cases
have diminished from 1,672,000 clinical cases with 4,650
deaths in 1991, to 91,635 with 43 deaths in 2006[6,7]. In
spite of current national guidelines recommending ACT,
artemisinin and artesunate are still available as mono-
therapy through the private sector (personal communica-
tion N. T. Tien). Self-treatment using anti-malarial drugs
purchased from private pharmacies may result in inade-
quate treatment regimes and the use of poor quality med-
icines, practices that favour the emergence of drug
resistance [8,9].
In 1998, the National Institute for Malariology, Parasi-
tology and Entomology (NIMPE) and researchers at the
University of Melbourne commenced monitoring in sen-
tinel sites in Vietnam to examine drug resistance
trends[10-12]. In Binh Phuoc province, the monitoring
sites were located approximately 100 km from the Cam-
bodian border. In this study, sensitivity to artemisinin and
artesunate was investigated in two sites in Binh Phuoc
province over 10 years. The in vivo and in vitro results are
presented for drug resistance monitoring surveys in 1998,
and 2001 in Phuoc Trung commune, and in 2004/5 and
2008/9 in Bu Gia Map commune.
Methods
Study sites
The study was conducted in Phuoc Long district, Binh
Phuoc province, which is located 130 km north-east of
Ho Chi Minh and 100 km west of the Cambodian border
(Figure 1). This province has a high prevalence of malaria
(> 10/1000 cases/year) with a peak season from Septem-
ber to December. It was the first province in Vietnam to
use artemisinin in 1989. For the studies in 1998 and 2001
patients were recruited in Phuoc Trung commune and for
the studies in 2004/5 and 2008/9, patients were recruited
from Bu Gia Map commune. The distance between the
two communes is about 80 kilometres, and both com-
munes are located in Phuoc Long district. The National
Malaria Control Programme first recommended the use
of a locally produced dihydroartemisinin-based combina-
tion therapy, CV8 (CV8 contains 4 drugs: 32 mg dihy-
droartemisinin, 320 mg piperaquine phosphate, 5 mg
primaquine phosphate and 90 mg trimethoprim) in these
communes in 2003, and then changed the recommenda-
tion to dihydroartemisinin-piperaquine ('Artekin') in
2007. In 2008 and 2009, CV8 was phased out and Artekin
became standard first-line treatment (N. T. Tien personal
communication, National Malaria Treatment Guidelines,
2007, 2009).
Recruitment of study participants
In vivo drug resistance monitoring surveys were per-
formed in September to November 1998 and 2001,
December 2004 to November 2005, and in September
2008 to March 2009, according to the WHO protocol
current at the time [13,14]. It was expected that between
50 and 75 patients would be recruited in each survey.
Patients presenting to the commune health centre with
uncomplicated  P. falciparum malaria, who were aged
three years and above and had asexual parasitaemia
between 1,000 and 200,000 parasites per μl were invited
to participate in the study. All participants 16 years and
above, and carers of those under 16 years, provided writ-
ten informed consent. Exclusion criteria included preg-
nancy, vomiting more than twice in the previous 24
hours, a convulsion in the previous 24 hours, or a history
of allergy to artemisinin or derivatives. Patients who had
received quinine, artemisinin or derivatives within the
last seven days, 4-aminoquinolines within the last 14
days, pyrimethamine and/or sulphonamides within the
last 28 days, or mefloquine within the last 56 days, were
excluded from the study. The parasite clearance time was
defined as the time from the initiation of therapy until the
first negative blood film that remained negative for 48
hours.
Blood samples were collected from all P. falciparum
positive cases before treatment, Blood smears were made
each day until two consecutive slides were negative and
on Day 7, 14, 21, 28, as well as from those who returned
with malaria symptoms. Blood was drawn by venipunc-
ture into a vacutainer tube containing EDTA. Thick and
thin blood smears were examined after staining with 5%
Giemsa. Parasitaemia was estimated by counting the
number of asexual parasites per 1,000 leucocytes in the
thick blood film, and estimates assumed a mean count of
8,000 leucocytes/μl.
Treatment of malaria and follow-up
Participants were treated with artemisinin for 5 days in
1998 (20 mg/kg on Day 0, 10 mg/kg on Day 1-4)
(Mediplantex, Hanoi, Vietnam), artemisinin for seven
days in 2001 (20 mg/kg on Day 0, 10 mg/kg on Day 1-6)
(Mediplantex, Hanoi, Vietnam), artesunate for seven days
in 2004/5 (4 mg/kg on Day 0, 2 mg/kg on Day 1-6) (Guilin
Pharma, Guilin, China; supplied by WHO), and artesu-
nate for seven days in 2008/9 (4 mg/kg on Day 0, 2 mg/kg
on Day 1-6, Naphaco, Nam Dinh province, Vietnam).
Naphaco is a Vietnamese manufacturer who was GMP
certified after inspection by WHO in 2008. Health clinic
staff directly observed all treatment doses.
Patients were observed in the health clinic for the first
seven days. If the patient vomited within 30 minutes after
administration, the full dose was repeated; if vomiting
occurred between 30 to 60 minutes after administration,
half the dose was repeated. Follow-up appointments were
scheduled for days 14, 21 and 28 or if they became unwell
and consisted of a physical examination, a blood sampleThanh et al. Malaria Journal 2010, 9:181
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and completion of a standardised data collection form. If
treatment failure occurred, patients were treated with
CV8 after blood (50 μl × 2) was collected by finger prick
and transferred onto 3 MM Whatman filter paper for
DNA analysis.
Treatment failure was defined according to WHO
guidelines [13].
In vitro drug sensitivity assays
In vitro micro-test plates (WHO plates) containing chlo-
roquine and mefloquine were prepared by Sain Penang
University, Malaysia. Piperaquine, dihydroartemisinin,
and artemisinin plates were freshly prepared by NIMPE
using WHO guidelines, and quinine plates were obtained
from WHO [10,15,16]. The artemisinin plates were used
within three months in the 1998, and 2001 surveys, and
within two weeks in 2004/2005 and 2008/9, and all plates
were stored at 4°C before use.
Blood was transferred to in vitro test plates and incu-
bated for 24 to 36 hours[15]. One of the 12 columns on
each plate was used for each patient blood sample. All the
wells of the appropriate column were dosed with 50 μl of
Figure 1 Map of malaria drug resistance monitoring sites in Phuoc Long district, Binh Phuoc Province, Vietnam. Arrows show sites in Phuoc 
Trung and Bu Gia Map communes. The border between Cambodia (Cam Pu Chia) and Vietnam is evident.Thanh et al. Malaria Journal 2010, 9:181
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the blood/medium mixture (BMM, 1: 9). Dosing started
with the control (well A) and followed an increasing order
of drug concentration ending at well H (the highest con-
centration). The plates were placed into a candle jar and
incubated at 37°C (± 0.5°C) for 24-36 hours. After incuba-
tion thick films were made from the pellet in each well of
the test plate and stained with 5% Giemsa for 30 minutes.
The test was considered valid if 10% or more of the para-
sites had reached schizont stage (three or more nuclei in
the plates) within 24-36 hours. The number of schizonts
per 200 parasites was used to assess maturation inhibi-
tion. Parasite isolates were classified as sensitive or resis-
tant to a particular drug according to the drug
concentration at which schizont maturation was com-
pletely inhibited [10,15,17].
PCR genotyping
Nested PCR was performed as described by Foley et al
[18] Nested PCR products were analyzed by electropho-
resis using 2% agarose for msp-1 and msp-2 and 1.5% aga-
rose for glurp. If the same genotype pattern was found in
both samples A and B (i.e. A = primary isolate, B = recur-
rent isolate), the infection was most likely to be a recru-
descence. In contrast, if the patterns of both samples
differed, a re-infection was assumed although it is possi-
ble that a minor population of the original infection was
responsible. It should also be noted that as specific para-
site genotypes are highly common in this region, a subject
who is infected with a genotype and then cured may be
reinfected with the same genotype (and thus misclassified
as a recrudescence).
Data analysis
Mean effective concentrations (EC) were calculated using
a computer adapted probit analysis of log-dose responses
[17] based on the methods of Litchfield and Wilcoxon
[19].
Discrete data were compared using the chi-square test.
Comparisons between two independent groups were
made using the student's t  test. Linear regression was
used to assess for a trend in parasite clearance times. The
correlation coefficients between the parameters of recent
treatments were determined by Spearman rank correla-
tion (r).
Ethics
Consultation was undertaken between the NIMPE team
and commune, district and provincial health staff. The
team provided patients with information regarding the
study and informed consent was documented at the time
of enrolment for the surveys. The project was approved
by the Human Research Ethics Committee of the
National Institute of Malariology, Parasitology and Ento-
mology (Hanoi, Vietnam), the Walter and Eliza Hall Insti-
tute of Medical Research (Melbourne, Australia) and
Melbourne Health (Melbourne, Australia).
Results and Discussion
The number of patients screened for malaria at each sur-
vey, diagnosed with malaria, recruited into each survey,
and the number of participants completing the treatment
course of artemisinin or artesunate is shown in Figure 2.
A total of 65 patients with uncomplicated P. falciparum
malaria completed a five-day treatment course with
artemisinin in the 1998 study, 69 patients completed
seven days treatment with artemisinin in 2001, and 82
and 54 patients completed seven days treatment with
artesunate in 2004/2005 and 2008/2009 respectively
(Table 1).
There were differences in mean parasite clearance
times between 1998, 2001 and 2004/5 (1.8, 2.3 and 2.1
days respectively, p < 0.01). Artemisinin given for seven
days (2001) had a slightly longer parasite clearance time
than artesunate for seven days in 2004/5 (2.3 compared
with 2.1, p = 0.13) and artesunate given for seven days in
2004/5 had a longer parasite clearance time than in 2008/
9 (2.1 compared with 1.6, p < 0.0001) (Tables 1 and 2).
However, linear regression analysis revealed that overall
there was no significant long-term trend in parasite clear-
ance time in the four surveys.
The mean parasite clearance times were positively cor-
related with parasite density at day 0 (r = 0.4; P < 0.001).
Overall 36.9% (24/65) patients had recrudescent parasi-
taemia during the 28-day surveillance period in 1998
after treatment with 5 days of artemisinin. The earliest
recrudescence occurred on Day 11. Six patients had a
recrudescence between days 11 and 14, 13 patients
between days 15 and 21, and five patients between days
22 and 26. Twelve of the 24 patients had a further parasite
recrudescence after retreatment with a five-day course of
artemisinin (2 occurred between days 11 and 14, 6
between days 15 and 21 and 4 on day 22 or 23). In 2001
the treatment schedule was changed to artemisinin for
seven days, and in 2004/2005 and 2008/2009, artesunate
was given for seven days. In these surveys, recrudescent
parasitaemia was confirmed microscopically in 7.2% (5/
69), 7.3% (6/82) and 3.7% (2/54) patients respectively. The
treatment failure rates after PCR confirmation were
13.8% (9/65), 2.9% (2/69), 1.2% (1/82), and 0% (0/54), in
the four surveys respectively. The proportion of patients
with persistent parasitaemia at day 3 was 6.2% in 1998,
8.7% in 2001, 3.7% in 2004/5 and 1.9% in 2008/9 (Table 2).
There was no difference in day 3 parasitaemia between
the 1998 and 2001 surveys (when artemisinin was used),
or between the 2004/5 and 2008/9 surveys (when artesu-
nate was used).
The results of drug susceptibility tests are shown in
Table 3. A total of 204 in vitro tests were successfullyThanh et al. Malaria Journal 2010, 9:181
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competed for chloroquine, 119 for mefloquine, 89 for
quinine, 172 for artemisinin, 81 for dihydroartemisinin
and 81 for piperaquine.
The mean EC50 for artemisinin was 30.5 nmol/L in
1998, 26.9 nmol/L in 2001, 13.7 nmol/L in 2004/5 and
17.4 nmol/L in 2008/9. There was a 4-fold increase in the
EC99 over the three year time period 1998 to 2001, (P <
0.001) but no difference between 1998 and 2008/9 (p =
0.127), and no difference between 2004/5 and 2008/9 (p =
0.511).
This study examined P. falciparum resistance patterns
over 10 years in infected patients treated with artemisinin
or artesunate in two sites in Phuoc Long district, Binh
Phuoc province, Vietnam, which were thought to be likely
sites for emerging resistance to artemisinin due to the
length of time that artemisinin-based compounds had
been in use. Seven day treatment with artesunate was
found to be effective in this area in 2008/9 with a recru-
descence rate from 0% to < 5% and no cases of early treat-
ment failures. There were no significant differences in
fever or parasite clearance times between the surveys
in1998 and 2008/9. Treatment failure rates reduced dur-
ing the period. These findings were supported by in vitro
testing of P. falciparum isolates, although tests in 2001
raised the possibility of reduced sensitivity to artesunate.
In the 1998 survey, patients were treated with five days
of monotherapy with artemisinin compared to treatment
with artemisinin or artesunate for seven days in later sur-
veys. The recurrent parasitaemia rate of 36.9% and treat-
ment failure rate of 13.8% confirms the lack of efficacy of
this approach[20]. Artesunate was used in the last two
surveys and showed improved parasite clearance and
reduced treatment failure rates compared to the first two
surveys, which used artemisinin. However, the surveys
were conducted at two different but nearby communes,
and it is possible that the two sites had different malaria
drug resistance patterns.
The reduced sensitivity to artemisinin in in vitro tests
in the 2001 survey raised the possibility of increasing P.
falciparum tolerance to artemisinin, although the signifi-
cance of reduced parasite sensitivity in EC90 and EC99
tests is not clear. Menard et al [21] found that 55 non-
immune patients living in Bangui, Central African
Republic, had parasitological cure rates of 100%, 95%, and
85% on days 14, 28, and 42, respectively. Although there
were no significant differences in parasitaemia density,
Figure 2 The number of patients screened for malaria with a blood film at each survey, diagnosed with malaria and P. falciparum, recruited 
into each survey, and who completed a treatment course and follow-up for 28 days is shown.
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50% inhibitory concentration of dihydroartemisinin, and
frequency of variant MDR1 codon 86 between patients
who were cured and those who displayed recrudescence,
the 90% inhibitory concentration for dihydroartemisinin
and the number of genotypes isolated were both higher in
the recrudescent patients (five- and two-fold, respec-
tively).
A more likely explanation for the increase in EC90 and
EC99 in the 2001 survey was deterioration of artemisinin
plates during the three months they were kept in the field
during the survey. To overcome this possibility plates
were replenished every two weeks in the 2004/5 and
2008/9 surveys. However, the reason for prolonged fever
clearance time and the higher day three parasitaemia in
the 2001 survey is not clear and the possibility remains
that the parasites circulating at the time were more toler-
ant to artemisinin than in the earlier survey. The use of
artesunate for treatment in the 2004/5 and 2008/9 sur-
veys, and the introduction of ACT (CV8) as routine treat-
ment in health centres in this district from 2003 may have
decreased the chance of drug resistant P. falciparum
infection being detected in the later surveys.
In vitro resistance of P. falciparum field isolates to arte-
mether and corresponding point mutations in the
SERCA-type PfATPase6 have been reported in French
Guiana and Senegal [22]. Also, artemisinin resistance has
recently been described on the Cambodia-Thai border [4]
and in Cambodia [5]. These studies confirmed the exis-
tence of P. falciparum resistance to artesunate in the
M e k o n g  r e g i o n  a l t h o u g h  t r e a t m e n t  f a i l u r e s  w i t h  A C T
remain low.
The limitations of this study included the use of differ-
ent formulations and treatment regimes with artemisinin
and artesunate in the four surveys. However, the design
of each survey was consistent with WHO protocols, and
treatment of patients was consistent with national
malaria treatment guidelines that were current at the
time. The first two surveys were also conducted at a dif-
Table 1: Baseline characteristics of study participants and clinical and parasite response to treatment
Characteristics 1998 2001 2004 - 2005 2008 - 2009
Antimalarial drugs 1 ART for 5 days ART for 7 days AS for 7 days AS for 7 days
Source of drugs Vietnam Vietnam China Vietnam
Number of patients 65 69 82 54
Age 22 ± 13 26 ± 13 19 ± 14 30 ± 14
Gender (M/F) 36/29 46/23 61/31 42/12
Temperature (°C) 38.4 ± 1.1 38.6 ± 1.1 38.1 ± 1.2 38.7 ± 1.1
Geometric mean of parasite (Range) 11,200
1,360 - 129,032
13,377
1,120 - 211,200
11,444
1,000 - 200,000
13,942
1,000 - 155,924
Fever Clearance Time (days)
Median
1.4 ± 0.5
1 (1 - 2)
1.7 ± 0.7
2 (1 - 4)
1.4 ± 0.6
1 (1 - 3)
1.4 ± 0.5
1 (1 - 2)
Parasite Clearance time (days)
Median
1.8 ± 0.9
2 (1 - 3)
2.3 ± 0.9
2 (1 - 3)
2.1 ± 0.7
2 (1 - 3)
1.6 ± 0.7
1 (1 - 3)
No. with recurrent parasitaemia (%) 24 (36.9%) 5 (7.2%) 6 (7.3%) 2 (3.7%)
Treatment failure after genotyping 9 (13.8%) 2 (2.9%) 1 (1.2%) 0 (0%)
1. ART = artemisinin, AS = artesunate
Table 2: Number of P. falciparum-infected patients (%) with parasitaemia on days 1-4 of treatment
1998 2001 2004/05 2008/09
Day 01 65 69 82 54
Day 1 40 (61.5) 29 (42.0) 73 (89) 26 (48.1)
Day 2 10 (15.4) 19 (27.5) 14 (17.1) 5 (9.3)
Day 3 4 (6.2) 6 (8.7) 3 (3.7) 1 (1.9)
Day 4 0 0 0 0
1. Day 0 is day of first diagnosis and commencement of treatment.Thanh et al. Malaria Journal 2010, 9:181
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ferent commune than the last two surveys. The two com-
munes were about 80 Km apart and although malaria
endemicity is similar at the two sites, it is possible that
different patterns of drug resistant malaria emerged at
each site during the study period. Anecdotal evidence
from a nearby district has suggested higher levels of per-
sistent parasitaemia on day 3, and this is currently being
investigated (NV Thanh, personal communication).
Another weakness was that although an adequate sample
of more than 50 patients was recruited in each survey not
all parasite isolates were able to be established in culture
for in vitro testing. There was also considerable loss to
follow-up in the 2001 survey. This and the non-random
selection of patients may have biased the results.
The main strengths of the study included the long fol-
low-up period over 10 years and the careful manner in
which the surveys were conducted. For each survey, the
same experienced national team was involved in recruit-
ing, treating and monitoring patients, who were given
directly observed therapy and monitored closely for the
first seven days. Artemisinin plates were replenished in
the field every three months in the first two surveys and
every two weeks in the last two surveys reducing the like-
lihood of plate deterioration.
Conclusions
This study has shown relatively stable levels of P. falci-
parum sensitivity to artemisinin compounds over a ten-
year period in two communes in Phuoc Long district,
Binh Phuoc province, Vietnam. The introduction of ACT
in 2003 may have protected against the spread of
artemisinin resistance in this area. Adherence to the lat-
est WHO and Vietnamese malaria treatment guidelines,
which recommend ACT as first line therapy in all malari-
ous areas, and consistent malaria control measures such
as early microscopic diagnosis, drug resistance monitor-
ing, provision and use of bed nets, and health worker
training will be essential if the development of resistance
to artemisinin-based compounds is to be prevented in
Vietnam.
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